CONRAD to host HIV symposium at 2nd Annual Antivirals Congress

November 05, 2012

Arlington, VA - CONRAD HIV and microbicides experts will be featured at the 2nd Annual Antivirals Congress organized by Elsevier publications. This year's conference is being held on November 11-13 at the Boston Marriott Cambridge. Executive and Scientific Director Gustavo Doncel and Director of Product Development David Friend will discuss ex vivo models for testing topical antiviral microbicides and current antiretroviral based microbicide products.

Other speakers at the CONRAD symposium include Tom Hope from Northwestern University and Patrick Kiser from the University of Utah who will speak on defining the interaction of HIV and the mucosal barriers exposed during sexual transmission, and novel microbicide dosage forms to prevent HIV transmission, respectively.

What: CONRAD Symposium: The Use of Antiviral Agents to Prevent HIV Transmission

When and Where: Monday, November 12th - 2:00-3:40PM - Boston Marriott Cambridge

CONRAD, a not for profit scientific organization based in Arlington, Virginia, specializes in developing new contraceptive methods and products to prevent or reduce HIV and other sexually transmitted infections. Several products in the pipeline focus on multi-purpose prevention options which provide contraception as well as HIV and STI protection. CONRAD tested and developed tenofovir gel, the first drug to show proof of concept that a vaginal gel containing antiretrovirals can reduce HIV and HSV-2 infections when used before and after sex.

Tenofovir is a drug commonly used by those infected with HIV to prevent the virus from multiplying in the immune system. A clinical study of women in South Africa who used a vaginal gel containing tenofovir has shown that it is 40-54 percent effective in reducing sexual transmission when used before and after sex.

The Antiretrovirals Congress provides state-of-the-art reports for scientists, health professionals and non governmental authorities to accelerate progress in the development and application of antivirals. The Congress serves as an interface between different interest groups from academia, those in research and development, regulatory and governmental agencies, charities, and health and industry professionals.
-end-
About CONRAD

CONRAD was established in 1986 and is a Division of the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA, where it has laboratories and a clinical research center. CONRAD is committed to improving reproductive health by researching and developing new contraceptive options and products to prevent HIV and sexually transmitted infections (STIs). The main office is located in Arlington, VA with collaborators around the world. www.conrad.org

CONRAD

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.